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ABSTRACT 24 
Conformational conversion of the cellular isoform of prion protein PrP
C
, into the 25 
abnormally folded, amyloidogenic isoform, PrP
Sc
, is a key pathogenic event in prion 26 
diseases including Creutzfeldt-Jakob disease in humans and scrapie and bovine 27 
spongiform encephalopathy (BSE) in animals. We previously reported that the 28 
octapeptide repeat (OR) region could be dispensable for converting PrP
C
 into PrP
Sc
 29 
after infection with RML prions. We demonstrated that mice transgenically expressing 30 
mouse PrP with deletion of the OR region on the PrP-knockout background, 31 
designated Tg(PrP∆OR)/Prnp0/0 mice, did not reduce susceptibility to RML scrapie 32 
prions, with abundant accumulation of PrP
Sc∆OR in their brains. We show here that 33 
Tg(PrP∆OR)/Prnp0/0 mice were highly resistant to BSE prions, developing the disease 34 
with markedly elongated incubation times after infection with BSE prions. The 35 
conversion of PrP∆OR into PrPSc∆OR was markedly delayed in their brains. These 36 
results suggest that the OR region may have a crucial role in the conversion of PrP
C
 37 
into PrP
Sc
 after infection with BSE prions. However, Tg(PrP∆OR)/Prnp0/0 mice 38 
remained susceptible to RML and 22L scrapie prions, developing the disease without 39 
elongated incubation times after infection with RML and 22L prions. PrP
Sc∆OR 40 
accumulated only slightly less in the brains of RML- or 22L-infected 41 
Tg(PrP∆OR)/Prnp0/0 mice than PrPSc in control wild-type mice. Taken together, these 42 
results indicate that the OR region of PrP
C
 could play a differential role in the 43 
pathogenesis of BSE prions and RML or 22L scrapie prions. 44 
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 45 
IMPORTANCE 46 
Structure-function relationship studies of PrP
C
 conformational conversion into PrP
Sc
 47 
are worthwhile to understand the mechanism of the conversion of PrP
C
 into PrP
Sc
. We 48 
show here that, by inoculating the three different prion strains RML, 22L and BSE 49 
prions, into Tg(PrP∆OR)/Prnp0/0 mice, the OR region could play a differential role in 50 
the conversion of PrP
C
 into PrP
Sc
 after infection with RML or 22L scrapie prions and 51 
BSE prions. PrP∆OR was efficiently converted into PrPSc∆OR after infection with 52 
RML and 22L prions. However, the conversion of PrP∆OR into PrPSc∆OR was 53 
markedly delayed after infection with BSE prions. Further investigation into the role 54 
of the OR region in the conversion of PrP
C
 into PrP
Sc
 after infection with BSE prions 55 
might be helpful for understanding the pathogenesis of BSE prions.  56 
 57 
KETWORDS: Prion, Prion protein, Octapeptide repeat, Bovine spongiform 58 
encephalopathy (BSE), Scrapie. 59 
60 
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INTRODUCTION 61 
Prions are causative agents of prion diseases, a group of fatal neurodegenerative disorders, 62 
which include Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker disease in 63 
humans and scrapie and bovine spongiform encephalopathy (BSE) in animals (1). Prions 64 
are believed to consist of the abnormally folded, relatively proteinase K (PK)-resistant 65 
isoform of prion protein, designated PrP
Sc
, and propagate through conformational 66 
conversion of the PK-sensitive, cellular isoform of PrP, PrP
C
, into PrP
Sc
 (1). PrP
C
 is a 67 
membrane glycoprotein tethered to the cell surface via a glycosylphosphatidylinositol 68 
moiety expressed most abundantly in the central nervous system, particularly by neurons (2). 69 
We and others have shown that mice devoid of PrP
C
 (Prnp
0/0
) are resistant to prions, neither 70 
developing the disease nor propagating prions even after intracerebral inoculation with the 71 
prions (3-6), clearly indicating that the conversion of PrP
C
 into PrP
Sc
 is a key pathogenic 72 
event in prion diseases.  73 
There is the so-called octapeptide repeat (OR) region, which consists of 5 copies 74 
of an octapeptide sequence in most mammalian species and 6 copies in a dominant 75 
population of cattle, in the N-terminal domain of PrP
C
 (7-10). Insertional mutations of one 76 
or more extra octapeptide sequences in the OR region leads to spontaneous conversion of 77 
the mutant PrP into the pathogenic PrP. This eventually causes hereditary prion diseases in 78 
humans (11). Transgenic mice expressing mouse PrP with an insertion of 9 additional OR 79 
sequences (14 OR sequences in total), designated Tg(PG14) mice, or bovine PrP with an 80 
insertion of an additional 4 OR sequences (10 OR sequences in total), bo10ORTg mice, 81 
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were shown to spontaneously develop neurodegenerative disease with accumulation of the 82 
relatively PK-resistant, but non-infectious PrP in their brains (12-14). Thus, insertion of 83 
extra octapeptide sequences in the OR region could render the mutant PrP structurally 84 
unstable, thereby causing conformational changes in the mutant PrP to form pathogenic PrP.  85 
Insertion of extra octapeptide sequences in the OR region has also been shown to 86 
increase susceptibility to BSE prions in mice. Bo10ORTg and bo7ORTg mice were reported 87 
to develop prion disease earlier than control bo6ORTg mice after infection with BSE prions 88 
(14, 15). Conversely, deletion of one octapeptide sequence in the OR region was reported to 89 
reduce susceptibility to BSE prions in mice (16). These results suggest that the OR region 90 
could have an important role in the pathogenesis of BSE prions. However, we previously 91 
showed that Prnp
0/0
 mice transgenic for mouse PrP with deletion of the OR region alone, 92 
designated Tg(PrP∆OR)/Prnp0/0 mice, did not have reduced susceptibility to RML scrapie 93 
prions, developing the disease without elongated incubation times after infection with RML 94 
prions (17). Taken together, these results suggest that the OR region could have a 95 
differential role in the pathogenesis of BSE and RML prions.  96 
In the present study, to verify this possibility, we intracerebrally inoculated 97 
Tg(PrP∆OR)/Prnp0/0 mice with BSE and RML prions. We also inoculated Tg mice with 22L 98 
scrapie prions. Tg(PrP∆OR)/Prnp0/0 mice inoculated with RML and 22L prions developed 99 
the disease without elongated incubation times. In contrast, incubation times were markedly 100 
elongated in Tg(PrP∆OR)/Prnp0/0 mice inoculated with BSE prions, with delayed 101 
accumulation of PrP
Sc∆OR in their brains. These results clearly show that the OR region 102 
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plays a differential role in the pathogenesis of BSE prions and RML or 22L scrapie prions. 103 
 104 
 105 
RESULTS 106 
Tg(PrP∆OR)/Prnp0/0 mice are highly resistant to BSE prions, but susceptible to RML 107 
and 22L prions  108 
To investigate the role of the OR region in prion pathogenesis, we intracerebrally inoculated 109 
Tg(PrP∆OR)/Prnp0/0 and C57BL/6 WT mice with RML, 22L, and BSE prions. As we 110 
previously reported (17), RML-inoculated Tg(PrP∆OR)/Prnp0/0 mice displayed foreleg 111 
paresis in addition to other disease-specific symptoms observed in control WT mice, such as 112 
emaciation, ruffled body hair, kyphosis, crossing leg, and paralysis of the hind legs. 113 
22L-inoculated Tg(PrP∆OR)/Prnp0/0 mice also developed foreleg paresis. Other symptoms 114 
were commonly observed in 22L-infected Tg(PrP∆OR)/Prnp0/0 and WT mice. BSE-infected 115 
Tg(PrP∆OR)/Prnp0/0 and WT mice developed similar symptoms. Consistent with our 116 
previous results (17), incubation and survival times were shortened in Tg(PrP∆OR)/Prnp0/0 117 
mice inoculated with RML prions compared to control WT mice (Table 1, p<0.0001). WT 118 
mice developed the disease at 159  2 (average  standard deviation) days post-inoculation 119 
(dpi) and became terminal at 175  3 dpi while incubation and survival times in 120 
Tg(PrP∆OR)/Prnp0/0 mice were shortened by 29 and 35 days, respectively (Table 1). 121 
Tg(PrP∆OR)/Prnp0/0 mice express PrP∆OR in their brains about 1.7 times more than PrPC 122 
in WT mice (Fig. 1A). The higher susceptibility of Tg(PrP∆OR)/Prnp0/0 mice to RML 123 
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prions could be due to higher expression of PrP∆OR in Tg(PrP∆OR)/Prnp0/0 mice than PrPC 124 
in WT mice. Tg(PrP∆OR)/Prnp0/0 mice also showed higher susceptibility to 22L prions than 125 
WT mice. Incubation and survival times were 143  1 and 156  2 dpi in control WT mice, 126 
but shortened by 32 and 24 days in Tg(PrP∆OR)/Prnp0/0 mice inoculated with 22L prions, 127 
respectively (Table 1, p<0.0001). In contrast, Tg(PrP∆OR)/Prnp0/0 mice exhibited markedly 128 
reduced susceptibility to BSE prions. Incubation and survival times were elongated by 141 129 
and 141 days, respectively, in Tg(PrP∆OR)/Prnp0/0 mice from 172  6 and 180  8 dpi in 130 
WT mice inoculated with BSE prions, respectively (Table 1, p<0.0001). These results show 131 
that Tg(PrP∆OR)/Prnp0/0 mice are highly resistant to BSE prions, but remain susceptible to 132 
RML and 22L prions, indicating that the OR region could have a crucial role in 133 
determination of the susceptibility to BSE prions in mice.   134 
 To confirm that the reduced susceptibility to BSE prions in Tg(PrP∆OR)/Prnp0/0 135 
mice is not a specific phenotype in the Tg line used, we produced another line of 136 
Tg(PrP∆OR)/Prnp0/0 mice, hereafter referred to as Tg(PrP∆OR-3608)/Prnp0/0. They 137 
expressed PrP∆OR in their brains at a similar level to PrPC in Prnp+/0 mice (Fig. 1B). The 138 
expression levels of PrP∆OR in Tg(PrP∆OR-3608)/Prnp0/0 mice and PrPC in Prnp+/0 mice 139 
are at 45  9 and 51  5% of those of PrPC in WT mice, respectively (p=0.29). We thus 140 
intracerebrally inoculated BSE prions into Tg(PrP∆OR-3608)/Prnp0/0 mice and control 141 
Prnp
+/0
 mice as controls. Longer incubation times were also observed in 142 
Tg(PrP∆OR-3608)/Prnp0/0 mice after inoculation with BSE prions, compared to control 143 
Prnp
+/0
 mice (Table 2, p<0.0001). Prnp
+/0
 mice developed the disease at 274  6 dpi and 144 
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became terminal at 290  10 dpi while Tg(PrP∆OR-3608)/Prnp0/0 mice succumbed to the 145 
disease at 335  26 dpi, becoming terminal at 343  27 dpi (Table 2). The lower 146 
susceptibility of Tg(PrP∆OR-3608)/Prnp0/0 mice to BSE prions than that of Prnp+/0 mice 147 
despite the similar expression of PrP∆OR in Tg(PrP∆OR-3608)/Prnp0/0 mice to PrPC in 148 
Prnp
+/0
 mice reinforces that the OR region could have an important role in determination of 149 
the susceptibility to BSE prions.  150 
 151 
The OR region is not essential for the conversion of PrP
C
 into PrP
Sc
 and brain 152 
pathologies  153 
To investigate the role of the OR region in the conversion of PrP
C
 into PrP
Sc
, we 154 
investigated the brains of terminally ill Tg(PrP∆OR)/Prnp0/0 mice infected with RML, 22L, 155 
and BSE prions for PrP
Sc∆OR. To detect PrPSc∆OR, the brain homogenates were treated 156 
with PK and then subjected to Western blotting with 6D11 anti-PrP antibody (Ab), which 157 
recognizes residues 93-109 of mouse PrP. Consistent with our previous results (17), 158 
PrP
Sc∆OR was detected slightly but significantly less in the brains of RML-infected, 159 
terminally ill Tg(PrP∆OR)/Prnp0/0 mice than PrPSc in control WT mice (Fig. 2A, p=0.006). 160 
PrP
Sc∆OR was also detected in the brains of 22L-infected, terminally ill 161 
Tg(PrP∆OR)/Prnp0/0 mice slightly less than PrPSc in control WT mice (Fig. 2B, p=0.136). 162 
However, PrP
Sc∆OR was accumulated in the brains of BSE-infected, terminally ill 163 
Tg(PrP∆OR)/Prnp0/0 mice more abundantly than PrPSc in control WT mice (Fig. 2C, 164 
p=0.028). Immunohistochemistry revealed indistinguishable staining for PrP
Sc
 and 165 
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PrP
Sc∆OR throughout the brain slices of terminally ill WT and Tg(PrP∆OR)/Prnp0/0 mice 166 
infected with RML, 22L, and BSE prions (Fig. 3A-D). These results indicate that, while the 167 
OR region is not essential for the conversion of PrP
C
 into PrP
Sc
 after infection with prions, it 168 
could affect the final accumulation levels of PrP
Sc
 in brains in a strain-dependent manner. 169 
 We also pathologically investigated the brains of RML-, 22L-, and BSE-infected, 170 
terminally ill Tg(PrP∆OR)/Prnp0/0 and WT mice for vaculolation. No significant difference 171 
in the number of vacuoles was detected in each brain area between Tg(PrP∆OR)/Prnp0/0 and 172 
WT mice infected with RML, 22L, and BSE prions (Fig. 4A-D, Fig. 5A-D), suggesting that 173 
PrP
Sc∆OR and PrPSc might be similarly pathogenic in brains.  174 
 175 
Delayed brain accumulation of PrP
Sc∆OR in BSE-infected Tg(PrP∆OR)/Prnp0/0 mice  176 
To gain insights into the reduced susceptibility of Tg(PrP∆OR)/Prnp0/0 mice to BSE prions, 177 
we sacrificed WT and Tg(PrP∆OR)/Prnp0/0 mice at 190 dpi with BSE prions and compared 178 
the levels of PrP
Sc∆OR accumulated in the brains of Tg(PrP∆OR)/Prnp0/0 mice to those of 179 
PrP
Sc
 in WT mice. WT mice were terminally ill around 190 dpi. However, 180 
Tg(PrP∆OR)/Prnp0/0 mice were still healthy by 190 dpi. PrPSc∆OR was detected at very low 181 
levels in Tg(PrP∆OR)/Prnp0/0 mice, compared to those of PrPSc in WT mice (Fig. 6A and B, 182 
p=0.0007). These results indicate that the conversion of PrP∆OR into PrPSc∆OR is less 183 
efficient than that of full-length PrP
C
 into PrP
Sc
 after infection with BSE prions, suggesting 184 
that the OR region could be important for BSE prions to convert PrP
C
 into PrP
Sc
. It is 185 
therefore possible that the reduced susceptibility to BSE prions in Tg(PrP∆OR)/Prnp0/0 186 
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mice could be attributable to the inefficient conversion of PrP∆OR into PrPSc∆OR after 187 
infection with BSE prions. 188 
  189 
The pre-OR region in PrP
Sc∆OR is PK-resistant  190 
We previously showed that the pre-OR region consisting of residues 23-50 of PrP
Sc∆OR 191 
produced in the brains of RML-infected Tg(PrP∆OR)/Prnp0/0 mice forms a PK-resistant 192 
conformation (17). To investigate whether or not 22L and BSE prions could also convert the 193 
pre-OR region into a PK-resistant structure upon the conversion of PrP∆OR into PrPSc∆OR, 194 
we treated 22L- and BSE-infected as well as RML-infected Tg(PrP∆OR)/Prnp0/0 brain 195 
homogenates with PK. They were then subjected to Western blotting with IBL-N anti-PrP 196 
Abs, which were raised against a pre-OR synthetic peptide comprising of residues 24-37 197 
(18). The Abs exhibited no PK-resistant signals in the RML-, 22L-, and BSE-infected WT 198 
brain homogenates (Fig. 7A-C). This is consistent with the pre-OR region of full-length 199 
PrP
Sc
 being PK-sensitive. However, PK-resistant signals were observed in the RML-, 22L-, 200 
and BSE-infected Tg(PrP∆OR)/Prnp0/0 brain homogenates (Fig. 7A-C), indicating that the 201 
pre-OR region of PrP
Sc∆OR is converted into a PK-resistant structure after infection with 202 
RML, 22L, and BSE prions.  203 
 204 
Tg(PrP∆OR)/Prnp0/0 mice are also highly resistant to secondarily inoculated 205 
PrP
Sc∆OR-BSE prions  206 
Differences in the primary sequence between PrP
C
 in recipient animals and PrP
Sc
 in an 207 
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inoculum often create the so-called prion transmission barrier leading to elongation of 208 
incubation times in recipient animals (19). If a prion transmission barrier is responsible for 209 
longer incubation times in primary inoculated mice, secondary inoculation into mice with 210 
the same genotype causes shorter incubation times. To investigate whether or not PrP∆OR 211 
might create a prion transmission barrier against full-length PrP
Sc
 and thereby render 212 
Tg(PrP∆OR)/Prnp0/0 mice less susceptible to BSE prions, we secondarily inoculated 213 
Tg(PrP∆OR)/Prnp0/0 and WT mice by the intracerebral route with brain homogenates from 214 
BSE-infected, terminally ill Tg(PrP∆OR)/Prnp0/0 mice containing PrPSc∆OR. We also 215 
secondarily inoculated Tg(PrP∆OR)/Prnp0/0 and WT mice with brain homogenates from 216 
RML- and 22L-infected, terminally ill Tg(PrP∆OR)/Prnp0/0 mice. Similar clinical 217 
symptoms were observed in Tg(PrP∆OR)/Prnp0/0 mice as well as WT mice after primary 218 
and secondary inoculation with RML-, 22L-, or BSE-infected Tg(PrP∆OR)/Prnp0/0 brain 219 
homogenate. Incubation times were slightly but not significantly shorter in 220 
Tg(PrP∆OR)/Prnp0/0 mice secondarily inoculated with RML-infected Tg(PrP∆OR)/Prnp0/0 221 
brain homogenates, compared to control WT mice (Table 3, p>0.3). 22L-infected 222 
Tg(PrP∆OR)/Prnp0/0 brain homogenates caused significantly shorter incubation times in 223 
Tg(PrP∆OR)/Prnp0/0 mice than in WT mice (Table 3, p<0.001). However, incubation times 224 
were still longer in Tg(PrP∆OR)/Prnp0/0 mice than in WT mice even after secondary 225 
inoculation with the BSE-infected Tg(PrP∆OR)/Prnp0/0 brain homogenate (Table 3). WT 226 
mice developed the disease at 165  8 dpi whereas Tg(PrP∆OR)/Prnp0/0 mice succumbed to 227 
the disease with longer incubation times of 307  9 dpi (Table 3, p<0.0001). These results 228 
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indicate that the different primary sequence between PrP∆OR and WT PrPSc does not create 229 
a transmission barrier for BSE prions.  230 
 231 
WT mice infected with PrP
Sc
- and PrP
Sc∆OR-prions accumulate PrPSc with the same 232 
biochemical properties  233 
To assess the pathogenic effects of PrP
Sc∆OR-prions on the conversion of PrPC into PrPSc, 234 
we investigated accumulation levels, the PK-resistant core size, and glycosylation patterns 235 
of PrP
Sc
 molecules in the brains of WT mice inoculated with RML-, 22L-, or BSE-infected 236 
Tg(PrP∆OR)/Prnp0/0 and WT brain homogenates containing PrPSc∆OR and PrPSc, 237 
respectively. Western blotting with 6D11 anti-PrP Ab revealed similar amounts of PrP
Sc
 238 
accumulated in terminally ill WT mice inoculated with PrP
Sc
 and PrP
Sc∆OR of RML, 22L, 239 
or BSE prions (Fig. 8A). Similar migration patterns were also observed for PrP
Sc
 in WT 240 
mice inoculated with RML-, 22L-, or BSE-PrP
Sc
 and -PrP
Sc∆OR (Fig. 8A). The 241 
deglycosylated, PK-resistant fragment of PrP
Sc
 in these brains also showed the same 242 
migration distance (Fig. 8B). These results suggest that the PK cleavage site is the same for 243 
PrP
Sc
 produced after inoculation with RML-, 22L-, or BSE-PrP
Sc
 and -PrP
Sc∆OR. We also 244 
investigated glycosylation patterns of PrP
Sc
 in these brains. The ratio of di-, mono-, and 245 
un-glycosylated forms of PrP
Sc
 in WT mice inoculated with RML-, 22L-, or BSE-PrP
Sc∆OR 246 
were similar to those of PrP
Sc
 in WT mice inoculated with RML-, 22L-, or BSE-PrP
Sc
 (Fig. 247 
8C). Taken together, these results indicate that the biochemical properties of PrP
Sc
 produced 248 
in WT mice after inoculation with PrP
Sc
- and PrP
Sc∆OR-prions are similar, suggesting that 249 
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PrP
Sc∆OR-prions might have the same pathogenic properties as PrPSc-prions. 250 
 251 
DISCUSSION 252 
In the present study, we studied the role of the OR region for PrP
C
 to support prion infection 253 
by inoculating RML, 22L, and BSE prions into Tg(PrP∆OR)/Prnp0/0 mice, which express 254 
PrP with a deletion of the OR region alone on the Prnp
0/0
 background. Compared to control 255 
WT mice, Tg(PrP∆OR)/Prnp0/0 mice had accelerated disease, exhibiting shorter incubation 256 
times after infection with RML and 22L prions. Shorter incubation times in RML-inoculated 257 
Tg(PrP∆OR)/Prnp0/0 mice are consistent with our previous results (17). The length of 258 
incubation times inversely correlates to the expression levels of PrP
C
 in animals infected 259 
with prions (20). Tg(PrP∆OR)/Prnp0/0 mice express PrP∆OR in their brains more than PrPC 260 
in WT mice. Therefore, the higher susceptibility of Tg(PrP∆OR)/Prnp0/0 mice to RML and 261 
22L prions could be due to the higher expression of PrP∆OR in their brains, suggesting that 262 
the OR region of PrP
C
 might be dispensable for RML and 22L infection in mice. In contrast, 263 
in spite of the higher expression of PrP∆OR, Tg(PrP∆OR)/Prnp0/0 mice were highly 264 
resistant to BSE prions, exhibiting markedly elongated incubation times after infection with 265 
BSE prions, indicating that the OR region could play a crucial role for PrP
C
 to support BSE 266 
infection in mice. 267 
The so-called prion transmission barrier often occurs when PrP
Sc
 in an inoculum 268 
and PrP
C
 in recipient animals differ in primary sequence, interfering with prion infection 269 
and eventually causing elongated incubation times in the recipient animals (21, 22). 270 
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However, Tg(PrP∆OR)/Prnp0/0 mice remained highly resistant to BSE prions, developing 271 
the disease with longer incubation times than WT mice, even after secondary inoculation 272 
with brain homogenates from BSE-infected, terminally ill Tg(PrP∆OR)/Prnp0/0 mice, which 273 
contain PrP
Sc∆OR. The longer incubation times of Tg(PrP∆OR)/Prnp0/0 mice secondarily 274 
inoculated with PrP
Sc∆OR-associated BSE prions indicate that the reduced susceptibility of 275 
Tg(PrP∆OR)/Prnp0/0 mice to full-length PrPSc-associated BSE prions primarily inoculated is 276 
not due to the different primary sequences between PrP
Sc
 in the inoculum and PrP∆OR in 277 
the recipient mice. This reinforces the crucial role of the OR region in BSE infection. 278 
Similar strain-dependent different susceptibility has been reported in mice 279 
transgenically expressing PrP with specific mutations or deletions in the sequence. Prnp
0/0
 280 
mice transgenic for mouse PrP with a serine residue at codon 170, designated 281 
Tg(PrP-170S)/Prnp
0/0
 mice, became highly resistant to RML and 79A prions, but were still 282 
susceptible to 22L and ME7 prions (23). Tg(OvPrP-V136)/Prnp
0/0
 mice expressing ovine 283 
PrP with a valine residue at codon 136 on the Prnp
0/0
 background were still susceptible to 284 
SSBP1 prions, but became resistant to CH1641 prions (24). We previously reported that 285 
Tg(MHM2∆23-88)/Prnp0/0 mice, which express mouse-hamster chimeric PrP with the 286 
deletion of residues 23-88, became highly resistant to RML, but still susceptible to 22L 287 
prions (25). Elucidation of the mechanism for the strain-dependent susceptibility would be 288 
important for understanding of the pathogenesis of prion diseases.  289 
The conversion efficiency of PrP
C
 into PrP
Sc
 is a key factor determining prion 290 
susceptibility. Indeed, the pathogenic PrPs were undetectable or much less accumulated in 291 
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the brains of Tg(PrP-170S)/Prnp
0/0
, Tg(OvPrP-V136)/Prnp
0/0
, or Tg(MHM2∆23-88)/Prnp0/0 292 
mice inoculated with resistant prion strains, but not with susceptible prion strains (23-25). 293 
We also showed that PrP
Sc∆OR was accumulated much less in the brains of 294 
Tg(PrP∆OR)/Prnp0/0 mice than PrPSc in control WT mice at 190 dpi with BSE prions, 295 
indicating that, compared to the conversion of PrP
C
 into PrP
Sc, the conversion of PrP∆OR 296 
into PrP
Sc∆OR is much more inefficient after infection with BSE prions. However, RML- or 297 
22L-inoculated Tg(PrP∆OR)/Prnp0/0 mice accumulated PrPSc∆OR in their brains only 298 
slightly less than or similarly to PrP
Sc
 in control WT mice, respectively, suggesting that 299 
RML and 22L prions could efficiently convert PrP∆OR into PrPSc∆OR. The different 300 
efficiency of PrP∆OR to convert into PrPSc∆OR after infection with BSE prions and RML 301 
or 22L prions indicate that the OR region might be differently involved in the conversion of 302 
PrP
C
 into PrP
Sc
 after infection with BSE prions and RML or 22L prions. It is thus 303 
conceivable that the different role of the OR region in the conversion of PrP
C
 into PrP
Sc
 304 
could underlie the different susceptibility of Tg(PrP∆OR)/Prnp0/0 mice to BSE prions and 305 
RML or 22L prions.  306 
The conformational selection model has been proposed as a mechanism to explain 307 
the strain-dependent conversion of PrP
C
 into PrP
Sc
. PrP
Sc
 molecules from different strains 308 
are believed to adopt different conformations (21, 22). Indeed, two different prion strains of 309 
transmissible mink encephalopathy, HY and DY, have been shown to produce PrP
Sc
 with 310 
strain-specific, different PK cleavage sites (26). DY-PrP
Sc
 has a shorter PK-resistant 311 
fragment than HY-PrP
Sc
 (27). The different PK cleavage sites of DY-PrP
Sc
 and HY-PrP
Sc
 312 
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indicate different protein conformations of both molecules. The PK-resistant fragment of 313 
BSE-PrP
Sc
 is shorter than that of RML- and 22L-PrP
Sc
, indicating that BSE-PrP
Sc
 forms a 314 
different conformation from RML- and 22L-PrP
Sc
. The conformational selection model 315 
postulates that inoculated PrP
Sc
 could select host PrP
C
 as a substrate for conversion on the 316 
basis of its conformational compatibility with the host PrP
C
. Conformational incompatibility 317 
between inoculated PrP
Sc
 and host PrP
C
 leads to unsuccessful or insufficient conversion of 318 
the host PrP
C
 into PrP
Sc
, and vice versa, thereby inoculating PrP
Sc
 converting host PrP
C
 into 319 
PrP
Sc
 in a strain-dependent manner (21, 22). PrP∆OR might adopt a different conformation 320 
from WT PrP
C
, and the adopted conformation of PrP∆OR might be still compatible with 321 
RML- and 22L-PrP
Sc
, but not with BSE-PrP
Sc
,
 
therefore PrP∆OR being insufficiently 322 
converted into PrP
Sc∆OR. Structural studies have shown that the N-terminal domain of PrP, 323 
including the OR region, transiently interacts with the C-terminal globular domain, 324 
suggesting that the transient interaction might confer structural stability within the 325 
C-terminal globular domain (28, 29). Lack of the OR region might render the C-terminal 326 
globular domain of PrP∆OR structurally unstable, thereby reducing the conformational 327 
compatibility of PrP∆OR with BSE-PrPSc, but not with RML- and 22L-PrPSc. Alternatively, 328 
since the OR region binds Cu
2+
 ions via histidine residues (30), lack of Cu
2+
 ions might 329 
cause conformational incompatibility of PrP∆OR with BSE-PrPSc.  330 
Other mechanisms might also be possible. Upon the conversion of PrP
C
 into PrP
Sc
, 331 
the OR region undergoes conformational changes to form a trypsin-resistant structure (31). 332 
It is thus possible that the conformational changes of the OR region might be important for 333 
 18 
BSE prions to convert PrP
C
 into PrP
Sc
, therefore lack of the OR region reduces the 334 
conversion of PrP
C
 into PrP
Sc
 after infection with BSE prions. The N-terminal domain of 335 
PrP
C
, including the OR region, is highly flexible and displays a marked conformational 336 
heterogeneity (29, 32, 33). Therefore, it is also possible that lack of the OR region might 337 
reduce the N-terminal conformational heterogeneity in PrP∆OR, rendering PrP∆OR 338 
resistant to BSE prions, but not to RML and 22L prions. The conversion of PrP
C
 into PrP
Sc
 339 
has been suggested to take place on the cell surface and/or along the endocytic pathway to 340 
lysosomes (34, 35). The OR region has been shown to be important for internalization of 341 
PrP
C
 (36). Defective internalization of PrP∆OR might disturb conversion into PrPSc∆OR, 342 
specifically after infection with BSE prions. Further studies are needed to elucidate the 343 
mechanism of the strain-specific conversion of PrP
C
 into PrP
Sc
. Elucidation of the exact role 344 
of the OR region in the conversion of PrP
C
 into PrP
Sc
 after infection with BSE prions might 345 
be helpful for understanding strain-specific conversion of PrP
C
 into PrP
Sc
. 346 
At terminal stages, PrP
Sc∆OR was higher in the brains of BSE-infected 347 
Tg(PrP∆OR)/Prnp0/0 mice than PrPSc in control WT mice. However, PrPSc∆OR was 348 
accumulated slightly less or similarly in the brains of RML- or 22L-infected, terminally ill 349 
Tg(PrP∆OR)/Prnp0/0 mice, respectively, compared to PrPSc in control WT mice. This is 350 
consistent with our previous results that PrP
Sc∆OR was slightly lower in the brains of 351 
Tg(PrP∆OR)/Prnp0/0 mice than WT mice after infection with RML prions (17). 352 
Tg(PrP∆OR)/Prnp0/0 mice developed the disease earlier than WT mice after infection with 353 
RML and 22L prions whereas they succumbed to the disease much later than WT mice after 354 
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infection with BSE prions. Therefore, the different incubation times might affect the final 355 
levels of PrP
Sc∆OR in the brains of Tg(PrP∆OR)/Prnp0/0 mice infected with RML, 22L and 356 
BSE prions.  357 
The pre-OR region was converted into a PK-resistant structure upon the 358 
conversion of PrP∆OR into PrPSc∆OR, but not upon the conversion of full-length PrPC into 359 
PrP
Sc
. We showed that PrP
Sc
- and PrP
Sc∆OR-associated BSE prions were highly pathogenic 360 
in WT mice but poorly so in Tg(PrP∆OR)/Prnp0/0 mice. We also showed that PrPSc∆OR 361 
could have similar pathogenic properties to full-length PrP
Sc
. Similar amounts of PrP
Sc
, with 362 
the same PK-resistant core size and the same glycosylation patterns, were detected between 363 
the brains of terminally ill WT mice inoculated with PrP
Sc
- and PrP
Sc∆OR-associated prions. 364 
These results suggest that the PK-resistant pre-OR region might not affect the pathogenic 365 
properties of prions. 366 
We showed that the OR region could be differentially involved in the conversion 367 
of PrP
C
 into PrP
Sc
 after infection with BSE prions and RML or 22L prions, suggesting that 368 
PrP
C
 might be converted into PrP
Sc
 through an OR region-dependent or -independent 369 
mechanism in a strain-dependent way. The major PK cleavage site in PrP
Sc
 is usually 370 
located either within the C-terminal part of the OR region or in the region C-terminal to the 371 
OR region (37). BSE-PrP
Sc
 has a PK cleavage site outside of the OR region (37), therefore 372 
producing a shorter C-terminal fragment after PK treatment. In contrast, RML- and 373 
22L-PrP
Sc
s have a longer PK-resistant fragment, indicating that the PK cleavage site of 374 
RML- and 22L-PrP
Sc
s is within the OR region. It is thus interesting to speculate that PrP
Sc
 375 
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carrying a PK cleavage site outside of the OR region, like BSE-PrP
Sc
, might convert PrP
C
 376 
into PrP
Sc
 through the OR region-dependent mechanism. In contrast, PrP
Sc
 with a PK 377 
cleavage site within the OR region might convert PrP
C
 into PrP
Sc
 in the OR 378 
region-independent way. Investigation of other prions for the relationship between the role 379 
of the OR region in the conversion of PrP
C
 into PrP
Sc
 and location of the PK cleavage site in 380 
the corresponding PrP
Sc
s might be worthwhile for further understanding the mechanism for 381 
conversion of PrP
C
 into PrP
Sc
. 382 
 383 
 384 
MATERIALS AND METHODS 385 
Ethics statements 386 
The Ethics Committees of Animal Care and Experimentation of the University of 387 
Occupational and Environmental Health and Tokushima University approved this study 388 
(approval number AE08-013, T28-100). Animals were cared for in accordance with The 389 
Guiding Principle for Animal Care and Experimentation of the University of Occupational 390 
and Environmental Health and Tokushima University and with Japanese Law for Animal 391 
Welfare and Care. 392 
 393 
Antibodies 394 
The antibodies used in this study are as follow: 6D11 mouse anti-PrP Ab (SIG-399810, 395 
BioLegend, San Diego, USA), IBL-N rabbit anti-PrP Ab (18635, Immuno-Biological 396 
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Laboratories, Gunma, Japan), mouse anti-ß-actin Ab (A5441, Sigma-Aldrich, St. Louis, 397 
USA), anti-mouse IgG, HRP-linked Ab (NA931, GE Healthcare, Little Chalfont, England), 398 
and anti-rabbit IgG, HRP-linked Ab (NA934, GE Healthcare). 399 
 400 
Animals 401 
Tg(PrP∆OR)/Prnp0/0 mice with the C57BL/6 background were produced elsewhere (18). In 402 
brief, a transgene construct encoding PrP∆OR was injected into the zygotes of C57BL/6 403 
mice to generate Tg(PrP∆OR) mice as described elsewhere (38, 39). The resulting 404 
Tg(PrP∆OR) mice were successively mated with Zrch I Prnp0/0 mice, which had been 405 
backcrossed with C57BL/6 mice at least 9 times, to produce the line of Tg(PrP∆OR)/Prnp0/0 406 
mice. A new line of Tg(PrP∆OR)/Prnp0/0 mice, designated Tg(PrP∆OR-3608)/Prnp0/0 mic, 407 
were similarly produced in this study. Prnp
+/0
 mice were produced by mating of Zrch I 408 
Prnp
0/0
 mice with C57BL/6 mice. C57BL/6 mice were purchased from Charles River 409 
Laboratories Japan (Kanagawa, Japan). CD-1 mice were purchased from Japan SLC Inc. 410 
(Shizuoka, Japan). 411 
 412 
Prion inoculation 413 
BSE prions originate from the classical type of BSE and have been maintained in CD-1 WT 414 
mice by successive intracerebral inoculations (37). RML and 22L prions are passaged in 415 
C57BL/6 WT mice. Brains were removed from terminally ill mice infected with RML, 22L, 416 
or BSE prions. A single brain was homogenized (10%, w/v) in phosphate-buffered saline 417 
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(PBS, 11482-15, Nakalai tesque, Osaka, Japan) using Multi-beads shocker (Yasui Kikai, 418 
Osaka, Japan) and then diluted 1% with PBS. Two brain homogenates from RML, 22L, or 419 
BSE-infected mice were mixed in equal amounts to prepare a brain homogenate inoculum 420 
and the resulting inoculum was intracerebrally inoculated into 5-6 week-old C57BL/6 WT, 421 
Prnp
+/0
, or Tg(PrP∆OR)/Prnp0/0 mice with a 20 l-aliquot. Mice were diagnosed as sick 422 
when they developed more than five of the following features: emaciation, decreased 423 
locomotion, ruffled body hair, ataxic gait, kyphosis, priapism, upright tail, crossing leg, hind 424 
leg paresis, and foreleg paresis. Mice were also diagnosed as terminal when they became 425 
akinetic.  426 
 427 
Protease K and PNGase F treatment  428 
Brain homogenates (10%, w/v) were prepared in lysis buffer (50 mM Tris-HCl, pH 7.4, 429 
containing 0.5% Triton X-100, 0.5% sodium deoxycholate, and 150 mM NaCl) using 430 
Multi-beads shocker (Yasui Kikai). Protein concentration was determined by a 431 
bicinchoninic acid (BCA) protein assay kit (23225, Pierce, Rockford, USA) using bovine 432 
serum albumin (23209, Pierce) as a standard, and the homogenates were adjusted to 5 mg of 433 
protein/ml with the lysis buffer. For sample preparation for analysis of PrP
Sc
, aliquots of 100 434 
µl of the lysates were digested with 10 µg proteinase K (165-21043, PK, Wako Pure 435 
Chemical Industries, Osaka, Japan) at 37˚C for 30 min. Peptide N-glycosidase F (P0704L, 436 
PNGase F, New England Biolabs, Beverly, USA) was used according to the manufacturer's 437 
protocol. In brief, total proteins were denatured in Glycoprotein Denaturing Buffer (B1704S, 438 
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New England Biolabs, Beverly, USA) by heating at 100˚C for 10 min and incubated with 439 
PNGase F (New England Biolabs) in a reaction buffer containing GlycoBuffer 2 (B3704S, 440 
New England Biolabs) and 1% NP-40 (B2704S, New England Biolabs) at 37˚C for 1 h.  441 
The samples were finally mixed with sodium dodecyl sulfate (SDS) sample buffer (62.5 442 
mM Tris-HCl pH6.8, containing 5% SDS, 4% β-mercaptoethanol, 5% Glycerol, 0.04% 443 
bromophenol blue, and 3 mM EDTA) and heated at 95˚C for 10 min before being subjected 444 
to Western blotting. 445 
 446 
Western blotting 447 
Proteins were resolved by SDS-polyacrylamide gel electrophoresis and electrically 448 
transferred to an Immobilon-P PVDF membrane (IPVH00010, Millipore, Billerica, USA). 449 
After blocking with 1% non-fat dry milk in TBST (10 mM Tris-HCl, pH7.4, containing 450 
0.05% Tween-20, and 150 mM NaCl) at room temperature (RT) for 1 h, the membranes 451 
were washed 3 times with TBST at RT for 5 min and incubated with the first Ab at 4˚C 452 
overnight in TBST containing 0.5% non-fat dry milk. The membranes were then washed 3 453 
times with TBST at RT for 5 min, and incubated with horseradish peroxidase-conjugated 454 
secondary Ab at RT for 2h in TBST containing 0.5% non-fat dry milk. After washing 3 455 
times with TBST at RT for 5 min, immunoreactive proteins were visualized using 456 
Immobilon Western Chemiluminescent HRP substrate (WBKLS0500, Millipore) and 457 
detected by LAS-4000 mini chemiluminescence imaging system (Fuji Film, Tokyo, Japan). 458 
Signal intensities were determined by Image Gauge software (Fuji Film). 459 
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 460 
Hematoxylin-Eosin staining 461 
Paraffin-embedded samples were sectioned at 5 m. The sectioned samples were 462 
deparaffinized, rehydrated, and stained with Mayer’s hematoxylin solution (131-09665, 463 
Wako Pure Chemical Industries) and 1% Eosin Y solution (051-06515, Wako Pure 464 
Chemical Industries). After washing, the samples were mounted with Softmount 465 
(192-16301, Wako Pure Chemical Industries). 466 
 467 
Immunohistochemistry 468 
Paraffin-embedded samples were sectioned at 5 µm. After deparaffinized, and rehydrated, 469 
the samples were autoclaved in 1 mM HCl at 121˚C for 5 min and subsequently washed 470 
with PBS. The samples were digested with 50 µg/mL PK in PBS at 37˚C for 30 min, treated 471 
with 3 M guanidine thiocyanate at RT for 10 min and then washed with PBS. After blocking 472 
with 5% FBS in PBS at RT for 1 h, the samples were incubated with 6D11 anti-PrP Ab at 473 
RT for 2 h and washed with PBS. The samples were then treated with ImmPRESS 474 
REAGENT Anti-Mouse IgG (MP-7402, Vector Laboratories, Burlingame, USA) at RT for 1 475 
h. After washing with PBS, the samples were incubated with ImmPACT DAB Peroxidase 476 
Substrate (SK-4105, Vector Laboratories) for 180 sec for staining. 477 
 478 
Statistical analysis 479 
Survival and incubation times were analyzed using the Log-rank(Mantel-Cox) test. Other 480 
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data were analyzed using the Student’s t-test. 481 
 482 
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Figure legends 618 
FIG 1. PrP∆OR expression in the brains of Tg(PrP∆OR)/Prnp0/0 and 619 
Tg(PrP∆OR-3608)/Prnp0/0 mice. (A) Left panel: Western blotting with 6D11 anti-PrP Ab of 620 
the brains of WT (n=3), Tg(PrP∆OR)/Prnp0/0 (n=3), and Prnp0/0 mice (n=3). Right panel: 621 
Expression levels of PrP∆OR in Tg(PrP∆OR)/Prnp0/0 mice to PrPC in WT mice. (B) Left 622 
panel: Western blotting of the brains of WT (n=3), Prnp
+/0
 (n=3), Tg(PrP∆OR-3608)/Prnp0/0 623 
(n=3), and Prnp
0/0
 mice (n=3) with 6D11 anti-PrP Ab. Right panel. Expression levels of PrP
C
 624 
in Prnp
+/0
 mice and PrP∆OR in Tg(PrP∆OR-3608)/Prnp0/0 mice compared to PrPC in WT 625 
mice. AU, arbitrary unit. 626 
 627 
FIG 2. Different levels of PrP
Sc∆OR accumulated in the brains of Tg(PrP∆OR)/Prnp0/0 mice 628 
infected with RML, 22L, and BSE prions at terminal stages. Western blotting with 6D11 629 
anti-PrP Ab of the brains of terminally ill WT (n=3) and Tg(PrP∆OR)/Prnp0/0 mice (n=3) 630 
infected with RML (A), 22L (B), and BSE prions (C) after treatment with (+) or without (-) 631 
PK. Right panel, levels of PrP
Sc∆OR in Tg(PrP∆OR)/Prnp0/0 mice to PrPSc in WT mice. AU, 632 
arbitrary unit. ns, not significant, *, p<0.05; **, p<0.01. 633 
 634 
FIG 3. Indistinguishable distribution of PrP
Sc
 and PrP
Sc∆OR accumulated in the brains of 635 
terminally ill WT and Tg(PrP∆OR)/Prnp0/0 mice. Brain slices from uninfected (A) and RML- 636 
(B), 22L- (C), and BSE-infected (D) terminally ill WT (n=3 in each mouse group) and 637 
Tg(PrP∆OR)/Prnp0/0 mice (n=3 in each mouse group) were immunohistochemically stained 638 
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for PrP
Sc
 and PrP
Sc∆OR by 6D11 anti-PrP Ab using the HCl-autoclaving method. Three 639 
sections from each mouse brain were subjected to investigation of PrP
Sc
 and PrP
Sc∆OR 640 
distribution. Cx, Cerebral cortex; Hp, Hippocampus; Th, Thalamus; Cb, Cerebellum. Bar, 641 
100 µm. 642 
 643 
FIG 4. Similar vacuolation in the brains of terminally ill WT and Tg(PrP∆OR)/Prnp0/0 mice. 644 
Brain slices from uninfected (A) and RML- (B), 22L- (C), and BSE-infected (D) terminally 645 
ill WT (n=3 in each mouse group) and Tg(PrP∆OR)/Prnp0/0 mice (n=3 in each mouse group) 646 
were subjected to HE staining and vacuoles in 0.1 mm
2
 areas were counted in various brain 647 
regions, including the cerebral cortex, hippocampus, thalamus, and cerebellum, respectively. 648 
Three sections from each mouse brain were subjected to the counting of vacuoles. 649 
 650 
FIG 5. Similar pathologies in the brains of terminally ill WT and Tg(PrP∆OR)/Prnp0/0 mice 651 
infected with RML, 22L, or BSE prions. Brain slices from uninfected (A) and RML- (B), 652 
22L- (C), and BSE-infected (D) terminally ill WT (n=3 in each mouse group) and 653 
Tg(PrP∆OR)/Prnp0/0 mice (n=3 in each mouse group) were subjected to HE staining. Three 654 
sections from each mouse brain were used for the pathological examinations. Cx, Cerebral 655 
cortex; Hp, Hippocampus; Th, Thalamus; Cb, Cerebellum. Bar, 100 µm. 656 
 657 
FIG 6. Delayed accumulation of PrP
Sc∆OR in the brains of Tg(PrP∆OR)/Prnp0/0 mice 658 
infected with BSE prions. (A) Brain homogenates from WT (n=3) and Tg(PrP∆OR)/Prnp0/0 659 
 34 
mice (n=3) sacrificed at 190 dpi with BSE prions were treated with (+) or without (-) PK and 660 
then subjected to Western blotting with 6D11 anti-PrP Ab. (B) PrP
Sc
 and PrP
Sc∆OR levels in 661 
the lower panels of (A). AU, arbitrary unit. ***, p<0.001. 662 
 663 
FIG 7. The pre-OR region of PrP
Sc∆OR is PK-resistant, but not in WT PrPSc. Brain 664 
homogenates from terminally ill WT (n=3) and Tg(PrP∆OR)/Prnp0/0 mice (n=3) infected 665 
with RML (A), 22L (B), and BSE prions (C) were treated with (+) or without (-) PK and then 666 
subjected to Western blotting with IBL-N anti-PrP Abs. 667 
 668 
FIG 8. Biochemical characterization of PrP
Sc
 produced in WT mice after inoculation with 669 
full-length PrP
Sc
- and PrP
Sc∆OR-prions. (A) Western blotting with 6D11 anti-PrP Ab of the 670 
brains of terminally ill WT mice inoculated with RML-, 22L-, or BSE-infected WT and 671 
Tg(PrP∆OR)/Prnp0/0 brain homogenates. (B) Western blotting with 6D11 anti-PrP Ab of the 672 
brains of terminally ill WT mice inoculated with RML-, 22L-, or BSE-infected WT and 673 
Tg(PrP∆OR)/Prnp0/0 brain homogenates after treatment with PNGase F. (C) Percentage of 674 
the di-glycosylated, mono-glycosylated, and un-glycosylated forms of PrP
Sc
 in the brains of 675 
terminally ill WT mice inoculated with RML-, 22L-, or BSE-infected WT and 676 
Tg(PrP∆OR)/Prnp0/0 brain homogenates. 677 
 
Table 1. Incubation and survival times of WT and Tg(PrP∆OR)/Prnp0/0 mice inoculated with various prions.  
Prions Recipient mouse 
Expression 
level of PrP1 
(fold) 
Diseased mice 
/Total mice 
Incubation times2 
(average ± standard 
deviation, days) 
Survival times3 
(average ± standard 
deviation, days) 
P value4 
[Log-rank(Mantel-Cox
) Test] 
RML WT 1 18/18 159 ± 2 175 ± 3 <0.0001 Tg(PrP∆OR)/Prnp0/0  1.7 15/15 130 ± 7 140 ± 9 
22L WT 1 13/13 143 ± 1 156 ± 2 <0.0001 Tg(PrP∆OR)/Prnp0/0 1.7 16/16 111 ± 9 132 ± 14 
BSE WT 1 11/11 172 ± 6 180 ± 8 <0.0001 Tg(PrP∆OR)/Prnp0/0 1.7 21/21 313 ± 4 321 ± 4 
1Expression levels were compared to those of PrPC in WT mice using Western blotting (ref). 
2Times to the onset of disease. 
3Times to the terminal stage of disease. 
4 P values indicate significance of incubation and survival times between WT and Tg(PrP∆OR)/Prnp0/0 mice. 
 Table 2. Incubation and survival times of Prnp+/0 and Tg(PrP∆OR-3608)/Prnp0/0 mice inoculated with BSE prions.  
Prions Recipient mouse 
Expression 
level of PrP1 
(fold) 
Diseased mice 
/Total mice 
Incubation times2 
(average  standard 
deviation, days) 
Survival times3 
(average  standard 
deviation, days) 
P value4 
[Log-rank(Mantel-Cox) 
Test] 
BSE 
Prnp+/0 0.5 13/13 274  6 290  10 
<0.0001 Tg(PrP∆OR-3608)/Prnp0/0 0.5 12/12 335  26 343  27 
1
Expression levels were compared to those of PrP
C
 in WT mice using Western blotting (ref). 
2Times to the onset of disease. 
3Times to the terminal stage of disease. 
4
 P value indicates significance of incubation and survival times between Tg(PrP∆OR)/Prnp0/0 and Prnp+/0 mice. 
Table 3. Tg(PrP∆OR)/Prnp0/0 mice are still susceptible to RML and 22L prions, but highly resistant to BSE prions, even after 
secondary inoculation with RML, 22L, and BSE-infected Tg(PrP∆OR)/Prnp0/0 brain homogenates.  
Tg(PrP∆OR)/Prnp0/0 
brain homogenate 
inoculum 
Recipient mouse Diseased mice 
/Total mice 
Incubation times1 
(average  standard 
deviation, days) 
Survival times2 
(average  standard 
deviation, days) 
P value3 
[Log-rank(Mantel-Cox) 
Test] 
RML Wild-type 10/10 144  3 176  7 
>0.3 Tg(PrP∆OR)/Prnp0/0 10/10 145  7 164  15 
22L Wild-type 10/10 148  6 155  4 
<0.0001 Tg(PrP∆OR)/Prnp0/0 10/10 104  7 109  3 
BSE  Wild-type 6/6 165  8 179  9 
<0.001 Tg(PrP∆OR)/Prnp0/0 6/6 
 307  9 331  20 
1Times to the onset of disease. 
2Times to the terminal stage of disease. 
3P values indicate significance of incubation and survival times between Tg(PrP∆OR)/Prnp0/0 and WT mice. 
 








